Article
Thymidylate synthase genotype-directed neoadjuvant chemoradiation for patients with rectal adenocarcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Mar 2011
Tan Benjamin R, Thomas Fabienne, Myerson Robert J, Zehnbauer Barbara, Trinkaus Kathryn, Malyapa Robert S, Mutch Matthew G, Abbey Elliot E, Alyasiry Amer, Fleshman James W, McLeod Howard L
Abstract excerpt
PURPOSE: Downstaging (DS) of rectal cancers is achieved in approximately 45% of patients with neoadjuvant fluorouracil (FU) -based chemoradiotherapy (CRT). Polymorphisms in the thymidylate synthase gene (TYMS) had previously defined two risk groups associated with disparate tumor DS rates (60% v 22%). We conducted a prospective single-institution phase II study using TYMS genotyping to direct neoadjuvant CRT for...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.